CRNX vs SIGA
CRNX: Crinetics Pharmaceuticals is a clinical-stage biotechnology company developing small molecule precision medicines for rare endocrine diseases and related tumors. SIGA: SIGA is a biodefense-focused pharmaceutical company selling tecovirimat (TPOXX®), an FDA-approved smallpox antiviral, primarily to the U.S. Strategic National Stockpile and international governments.
Side-by-side fundamentals
| Metric | CRNX | SIGA | Edge |
|---|---|---|---|
| Price as of 2026-08-04 close | $83.86 | $3.24 | |
| Market cap as of 2026-08-05 | $8.8B | $232M | |
| P/E as of 2026-08-04 | n/a | 11.51 | |
| PEG as of 2026-08-05 | -0.73 | n/a | |
| Net margin as of 2026-08-05 | -2747.2% | +21.6% | SIGA higher |
| Gross margin as of 2026-08-05 | +86.0% | +65.4% | CRNX higher |
| Operating margin as of 2026-08-05 | -3020.3% | +22.0% | SIGA higher |
| ROE as of 2026-08-05 | -44.0% | +10.6% | SIGA higher |
| ROA as of 2026-08-05 | -39.6% | +8.9% | SIGA higher |
| Debt / equity as of 2026-08-05 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-05 | +2277.5% | -22.1% | CRNX higher |
| Revenue CAGR (3y) SEC XBRL | n/a | -5.1% | |
| Dividend yield as of 2026-08-04 | n/a | +18.5% | |
| Dividend streak (yrs) SEC XBRL | n/a | 4 | |
| Beta as of 2026-08-05 | 0.02 | 0.81 | |
| 1-year return as of 2026-08-04 close | +197.2% | -51.3% | CRNX higher |
Fundamentals: market data, as of 2026-08-05. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-04.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.